Early relief of osteoarthritis symptoms with a natural mineral supplement and a herbomineral combination: A randomized controlled trial [ISRCTN38432711]

Journal of Inflammation

Volumn 2, Issue , 2005, Pages

  Miller, Mark J S ^a   Mehta, Komal ^b   Kunte, Sameer ^b   Raut, Vidyanand ^c   Gala, Jayesh ^d   Dhumale, Ramesh ^e   Shukla, Anil ^b   Tupalli, Hemant ^b   Parikh, Himanshu ^b   Bobrowski, Paul ^f   Chaudhary, Jayesh ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b Vedic Lifesciences   (India)

^c Ashok Raut Orthopedic Hospital   (India)

^d Bhagwati Hospital   (India)

^e KJ Somaiya Medical College and Hospital   (India)

^f Santerra Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERBACEOUS AGENT; PARACETAMOL; PLACEBO; SIERRASIL; UNCARIA GUIANENSIS EXTRACT; UNCLASSIFIED DRUG;

ARTICLE; CAT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HUMAN; KNEE; LABORATORY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOARTHRITIS; PAIN; PARAMETER; PATIENT; RANDOMIZED CONTROLLED TRIAL; SAFETY; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOM; VISUAL ANALOG SCALE;

UNCARIA GUIANENSIS;

EID: 27744527299     PISSN: 14769255     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-2-11     Document Type: Article

References (44)

1. Murray CJL, Lopez AD: The Global Burden of Disease Boston: Harvard University Press; 1996.
2. Kraan PM, Berg WM: Anabolic and destructive mediators in osteoarthritis. Curr Opin Nutr Metab Care 2000, 3:205-211.
3. Dickman A, Ellershaw J: NSAIDs: gastroprotection or selective COX-2 inhibitor? Palliat Med 2004, 18:275-86.
4. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365:475-81.
5. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL: Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005, 142:157-64.
6. Berman BM, Lao L, Langenberg P, Lee WL, Gilpin AM, Hochberg MC: Effectiveness of acupuncture as adjunctive therapy in osteoarthritis of the knee: a randomized, controlled trial. Ann Intern Med 2004, 141:901-10.
7. Noack W, Fischer M, Forster KK, Rovarti LC, Setnikar A: Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage 1994, 2:61-69.
8. Walter-Bone K: 'Natural remedies' in the treatment of osteoarthritis. Drugs Aging 2003, 20:517-526.
9. Hesslink R, Armstrong D, Nagendra MV, Sreevatsan S, Barathur R: Cetylated fatty acids improve knee function in patients with osteoarthritis. J Rheumatol 2002, 29:1708-1712.
10. Piscoya J, Rodriuez Z, Bustamante SA, Okuhama NN, Miller MJS, Sandoval M: Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: mechanisms of action of the species Uncaria guianensis. Inflamm Res 2001, 50:442-448.
11. Ahmed S, Anuntiyo J, Malemud CJ, Haqqi TM: Biological basis for the use of botanicals in osteoarthritis & rheumatoid arthritis: a review. Evidence-Based Complimentary Alternative Medicine in press.
12. Baker K, McAlindon T: Exercise for knee osteoarthritis. Curr Opin Rheumatol 2000, 12:456-463.
13. Biggee BA, Blinn CM, McAlindon TE, Nuite M, Silbert JE: Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Ann Rheumatol 2005 in press.
14. Hua J, Sakamoto K, Nagaoka I: Inhibitory actions of glucosamine, a therapeutic agent for osteoarthritis, on the functions of neutrophils. J Leukoc Biol 2002, 71:632-640.
15. Pujalte JM, Llavore EP, Ylescupidez FR: Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of oseoarthrosis. Curr Med Res Opin 1980, 7:110-114.
16. Muller-Fassbender H, Bach GI, Haase W, Rovarti LC, Setnikar I: Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage 1994, 44:75-80.
17. Lopez Vas A: Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients. Curr Med Res Opin 1982, 8:145-149.
18. McAlindon T: Why are clinical trials of glucosamine no longer uniformly positive? Rheum Dis Clin North Am 2003, 29:789-801.
19. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al.: Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-256.
20. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli C, Rovarti LC: Glucosamine sulphate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002, 162:2113-2123.
21. McAlindon TE, Formica M, LaValley M, Lehmer M, Kabbara K: Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomized double-blind controlled trial. Am J Med 2004, 117:643-649.
22. Singh R, Ahmed S, Malemud CJ, Goldberg VM, Haqqi TM: Epigallocatechin-3- gallate selectively inhibits interleukin-1β-induced activation of mitogen activated protein kinase subgroup c-Jun N-terminal kinase in human osteoarthritis chondrocytes. J Orthopaedic Res 2003, 21:102-109.
23. Ahmed S, Rahman A, Hasnain A, Lalonde M, Goldberg VM, Haqqi TM: Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1β-induced activity and expression of cyclo-oxygenase-2 and nitric oxide synthase-2 activity in human chondrocytes. Free Radical Biology Med 2002, 33:1097-1105.
24. Haqqi TM, Anthony DD, Gupta S, Ahmed N, Lee M-S, Kumar GK, Mukhtar H: Prevention of collagen induced arthritis in mice by a phenolic fraction of green tea. Proc Natl Acad Sci USA 1999, 96:4525-4529.
25. Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, Mapp PI, Morris CJ, Blake DR, Kaltschmidt C, Baeuerle PA: Activation of the nuclear transcription factor-κB in human inflamed synovium. Arthritis Rheum 1996, 39:583-591.
26. Winyard PG, Blake DR: Antioxidants, redox-regulated transcription factors. Adv Pharmacol 1997, 18:403-421.
27. Lohmander LS: What can we do about osteoarthritis? Arthritis Res 2000, 2:95-100.
28. Ahmed S, Rahman A, Hasnain A, Goldberg VM, Haqqi TM: Pheny N-ter-butylnitrone down-regulates interleukin-1β-stimulated matrix metalloproteinase-13 gene expression in human chondrocytes: suppression of c-Jun NH2-terminal kinase, p38-mitogen-activated protein kinase and activating protein-1. J Pharmacol Exptl Ther 2003, 305:981-988.
29. Miller MJS, Ahmed S, Bobrowski P, Haqqi TM: Suppression of human cartilage degradation and chondrocyte activation by a unique mineral supplement (sierrasil™) and a cat's claw extract, vincaria® . J Amer Nutr Assoc 2004, 7:32-39.
30. Connor JR, Manning PT, Settle SL, Moore WM, Jerome GM, Webber RK, Tjoeng FS, Currie MG: Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur J Pharmacol 1995, 273:15-24.
31. Amin R, Abramson SB: The role of nitric oxide in articular cartilage breakdown in osteoarthritis. Curr Opin Rheumatol 1998, 10:263-268.
32. Murrell GA, Jang D, Williams RJ: Nitric oxide activates metalloproteinase enzymes in articular cartilage. Biochem Biophys Res Commun 1995, 206:15-21.
33. Clancy RM, Amin AR, Abramson SB: The role of nitric oxide in inflammation and immunity. Arthritis Rheum 1998, 41:1141-1151.
34. Miller MJS, Sadowska-Krowicka H, Chotinaruemol S, Kakkis JL, Clark DA: Amelioration of chonic ilieitis by nitric oxide synthase inhibition. J Pharmacol Exptl Ther 1993, 264:11-16.
35. Miller MJS, Thompson JH, Zhang XJ, Sadowska-Krowicka H, Kakkis JL, Munshi UK, Sandoval M, Rossi JE, Eloby-Childress S, Beckman JS, Ye YZ, Roddi CP, Manning PT, Currie MG, Clark DA: Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ilieitis. Gastroenterology 1995, 109:1475-1483.
36. Sandoval-Chacon M, Thompson JH, Liu X, Mannick EE, Sadowska-Krowicka H, Charbonnet R, Clark DA, Miller MJS: Anti-inflammatory actions of cat's claw: the role of NF-κB. Alimentary Pharmacol Ther 1998, 12:1279-1289.
37. Sandoval M, Charbonnet RM, Okuhama N, Roberts J, Krenova Z, Trentacosti AM, Miller MJS: Cat's claw inhibits TNFα production and scavenges free radicals: role in cytoprotection. Free Radical Biol Med 2000, 29:71-78.
38. Sandoval M, Okuhama NN, Zhang X-J, Condezo LA, Lao J, Angeles FM, Bobrowski P, Miller MJS: Anti-inflammatory and antioxidant activities of cat's claw (Uncaria tomentosa and Uncaria guianensis) are independent of their alkaloid content. Phytomedicine 2002, 9:325-337.
39. Miller MJS, Angeles FM, Reuter BK, Bobrowski P, Sandoval M: Dietary antioxidants protect gut epithelial cells from oxidant induced apoptosis. BMC Compl Altern Med 2001, 1:11.
40. Obregan LE: Cat's claw, Uncaria genus. In Botanical, Chemical and Pharmacological Studies of Uncaria tomentosa (Wiild.) D.C. (Rubiaceae) and Uncaria guianensis (Aubl.) Gmel Instituto de Fitotherapia Americano. Lima; 1995.
41. Wurm M, Kacani L, Laus G, Keplinger K, Dierich MP: Pentacyclic oxindole alkaloids from Uncaria tomentosa induce human endothelial cells to release a lymphocyte-proliferation-regulatory factor. Planta Medica 1998, 64:701-704.
42. Lemaire L, Assinewe V, Cano P, Awang DVC, Arnason JT: Stimulation of interleukin-1 and -6 production in alveolar macrophages by the neotropical liana, Uncaria tomentosa (Una de gato). J Ethnopharmacol 1999, 64:109-115.
43. McAlindon TE, Biggee BA: Nutritional factors and osteoarthritis: recent developments. Curr Opin Rheumatol 2005, 17:647-652.
44. Cibere J, Kopec JA, Thorne A, Singer J, Canvin J, Robinson DB, Pope J, Hong P, Grant E, Esdaile JM: Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheumat 2004, 51:738-745.